Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
- PMID: 3182080
- PMCID: PMC259734
- DOI: 10.1128/iai.56.12.3272-3279.1988
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
Abstract
Previous passive antibody transfer experiments have indicated that immunity to a 46-kilodalton membrane glycoprotein (M-2) of Leishmania amazonensis may protect against infection with this parasite. In the studies described in this paper, we investigated the ability of the purified M-2 molecule to elicit a protective immune response in conjunction with Freund incomplete and complete adjuvants, saponin, and Corynebacterium parvum. Both relatively susceptible (BALB/c and CBA) and resistant (C57BL/6) strains of mice were examined. C. parvum appeared to be the most effective adjuvant in the three mouse strains tested. The level of protection varied with the mouse strain, although all animals received identical preparations of antigen and adjuvant. Immunization of CBA mice with the M-2 glycoprotein and C. parvum resulted in complete protection against a challenge infection of 10(4) and 10(6) late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms). The level of protection observed is reflected by increased antibody response (immunoglobulins G1 and G2) developed to the M-2 molecule. The relationship of pure T-cell (nonantibody) immunity to this protection remains to be elucidated.
Similar articles
-
Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.J Immunol. 1987 Jul 1;139(1):221-7. J Immunol. 1987. PMID: 3495599
-
Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.Infect Immun. 1995 Sep;63(9):3559-66. doi: 10.1128/iai.63.9.3559-3566.1995. Infect Immun. 1995. PMID: 7642292 Free PMC article.
-
Total Leishmania antigens with Poly(I:C) induce Th1 protective response.Parasite Immunol. 2017 Nov;39(11). doi: 10.1111/pim.12491. Epub 2017 Oct 9. Parasite Immunol. 2017. PMID: 28901553
-
Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.Microbes Infect. 2010 Nov;12(12-13):967-77. doi: 10.1016/j.micinf.2010.06.008. Epub 2010 Jul 1. Microbes Infect. 2010. PMID: 20601076
-
Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.Microbes Infect. 2007 Jul;9(9):1070-7. doi: 10.1016/j.micinf.2007.05.012. Epub 2007 May 16. Microbes Infect. 2007. PMID: 17644455
Cited by
-
Engineering and design of promising T-cell-based multi-epitope vaccine candidates against leishmaniasis.Sci Rep. 2023 Nov 8;13(1):19421. doi: 10.1038/s41598-023-46408-1. Sci Rep. 2023. PMID: 37940672 Free PMC article.
-
Biochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8.Infect Immun. 2001 Nov;69(11):6776-84. doi: 10.1128/IAI.69.11.6776-6784.2001. Infect Immun. 2001. PMID: 11598050 Free PMC article.
-
The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.J Cell Sci. 2016 Aug 15;129(16):3130-43. doi: 10.1242/jcs.185595. Epub 2016 Jun 29. J Cell Sci. 2016. PMID: 27358479 Free PMC article.
-
Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.Infect Immun. 2003 Jan;71(1):401-10. doi: 10.1128/IAI.71.1.401-410.2003. Infect Immun. 2003. PMID: 12496190 Free PMC article.
-
Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.Clin Exp Immunol. 2005 Apr;140(1):149-56. doi: 10.1111/j.1365-2249.2005.02745.x. Clin Exp Immunol. 2005. PMID: 15762886 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical